AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Nasser Mikhail, Endocrinology Division1, Department of Medicine, Olive View-UCLA Medical Center,David-Geffen UCL AMedicalSchool, CA ,USA
Citation: Nasser Mikhail, (2024), Efficacy and Safety of Once-Weekly Insulin Icodec. J. Pharmaceutics and Pharmacology Research, 7(1); DOI:10.31579/2688-7517/152
Copyright: © 2024, Nasser Mikhail. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 10 October 2023 | Accepted: 23 November 2023 | Published: 15 January 2024
Keywords: insulin; icodec; glargine; degludec; hypoglycemia; diabetes; glycated hemoglobin
Insulin icodec is a long-acting once-weekly basal insulin analog that is currently under investigations. Efficacy and safety of insulin icodec were assessed in a series of 6 phase 3 clinical trials known as the ONWARDS Program; 5 trials in type 2 diabetes, and 1 trial in type 1 diabetes. In 4 of the 6 ONWARDS trials, reductions in glycated hemoglobin (HbA1c) levels were slightly greater with insulin icodec compared with once-daily insulin glargine or degludec with a mean difference of 0.19-0.38 percentage points. In the other 2 trials, insulin icodec was not inferior to insulin degludec in reducing HbA1c levels. Data analysis of continuous glucose monitoring (CGM) showed greater or similar time spent in range (TIR) with insulin icodec versus insulin glargine or degludec. In type 2 diabetes, patient satisfaction and compliance were superior with insulin icodec compared with insulin glargine or degludec. However, in type 1 diabetes, satisfaction score was lower with insulin icodec than with degludec. Incidence of level 1 hypoglycemia [blood glucose (BG) levels 54-69 mg/dl] was higher with insulin icodec compared with insulin glargine or degludec with estimated rate ratio (ERR) ranging from 1.25 to 1.88. In 3 of the 6 ONWARDS trials, incidence of combined level 2 hypoglycemia (clinically significant hypoglycemia with BG < 54 mg/dl) and level 3 hypoglycemia (severe hypoglycemia with cognitive impairment requiring external assistance) was significantly higher (by 71-89%) with insulin icodec vs insulin glargine or degludec. In patients with type 1 diabetes, incidence of hypoglycemia (levels 1, 2, 3, and nocturnal) was substantially higher with insulin icodec versus insulin. In general, no significant differences in weight were recorded between subjects receiving insulin icodec and those receiving insulin degludec. Allergic reactions were not increased with use of insulin icodec. In conclusion, insulin icodec may be a convenient basal insulin that is administered once weekly. It is similar or slightly higher in efficacy compared with insulin glargine or degludec. Yet, it is associated with increased incidence of hypoglycemia, particularly in type 1 diabetes.
Insulin icodec has a half-life of 196 hours (8.1 days) allowing its administration once weekly [1,2]. After reaching a steady state 3-4 weeks following its initiation, insulin icodec exhibits an evenly distributed glucose-lowering activity throughout the 7 days of the week [1-2]. The long duration of action of insulin icodec is attributed to 2 main factors. First, binding to albumin through addition of a C20 fatty acid-containing side chain to form an albumin-binding depot from which icodec is slowly released in the circulation. Second, 3 amino acid substitutions that decreases affinity of icodec to insulin receptors leading to its decreased rate of clearance. Normally, insulin clearance occurs primarily through internalization following binding of insulin to its receptors at cell surface. Thus, reduced binding of insulin icodec to insulin receptors will lead to its reduced clearance and further prolongation of its action [1,2]. Importantly, the reduced affinity of icodec to insulin receptor does not compromise its potency but slows its action [1,2]. The concentration of formulation of insulin icodec is 7 times higher than that of the standard insulin U100 formulation. Consequently, the volume of insulin icodec administered once weekly is similar to other basal insulin dosing volumes given once daily [1,2]. The ONWARDS Program consists of 6 phase 3 clinical trials to evaluate insulin icodec versus insulin degludec and gargine [1]. In a previous article, the author reviewed the pharmacologic properties of insulin icodec as well as its efficacy and safety in 5 of the 6 trials of the ONWARDS Program including patients with type 2 diabetes [1]. More recently, insulin icodec was evaluated in subjects with type 1 diabetes in the 6th and last trial of the ONWARDS Program [3-8]. The main objective of this article is to review the efficacy and safety of insulin icodec in patients with type 1 and type 2 diabetes.
Summary of the ONWARDS studies
Table 1 summarizes the main features and results of the 6 ONWARDS trials [3-8]. The 6 trials were randomized, multinational and treat-to target [3-8]. The primary endpoint was the change in HbA1c levels from baseline to the end of the study. The target of fasting self-measured BG was 80-130 mg/dl. Thus, doses of insulin icodec, glargine and degludec were modified weekly based on 3 pre-breakfast BG readings to attain this glycemic target [1]. The process of titration was mentioned in detail in a previous article of the author [1]. Briefly, if the mean of the self-measured 3 BG values are > 130 mg/dl, insulin icodec dose is increased by 20 units weekly and doses of glargine or degludec are increased by 3 units daily. On the other hand, if the lowest of the 3 fasting BG values is < 80 n=1,805),>
Effects of insulin icodec on glycemic control
In ONWARDS 1, 2, 3, and 5 insulin icodec was shown to be slightly but statistically superior to both glargine glargine and degludec in reducing HbA1c values, with estimated treatment difference (ETD) of approximately 0.19 to 0.38 percentage points (table 1) [3-5,7]. In ONWARDS 4 and 6, insulin icodec was not inferior than degludec with respect to HbA1c reduction (table 1) [6,8]. In the 5 studies including patients with type 2 diabetes, reductions in HbA1c levels were evident 10-13 weeks after starting insulin in all treatment groups, then attained a trough at week 26 followed by a plateau [3-7]. Meanwhile, in type 1 diabetes, HbA1c levels reached a trough earlier after 10 weeks followed by gradual rebound [8]. Information from CGM was used for a duration of 4 weeks in ONWARDS 1, 2 and 6 trials to identify the diurnal glycemic trajectory [3,4,8]. In general, no significant differences in time spent in range (70-180 /dl) was recorded between icodec groups and glargine or degludec [3,4,8]. Meanwhile, in ONWARDS 1 trial, the percentage of time spent with BG levels above the range (ie. > 180 mg/dl) was approximately 1 hour less with insulin icodec than with insulin glargine [3]. While insulin efficacy depends largely on its doses, there was no consistent trend with respect to differences in insulin doses between insulin icodec and other basal insulins (table 1).
Patient satisfaction with insulin icodec
Patient satisfaction with insulin icodec versus degludec was assessed in ONWARDS 2, 5,6 and 8 studies using the validated “Diabetes Treatment Satisfaction Questionnaire” (DTSQ) with higher score indicating greater satisfaction [4,7,8]. In ONWARDS 2, at week 26, the DTSQ score was slightly but significantly higher in patients randomized to insulin icodec than insulin degludec 4.22 and 2.96, respectively; ETD 1.25 (95% CI, 0.41 to 2.10, P=0.003) (table 1) [4]. In ONWARDS 5, the corresponding ETD was smaller, but still statistically significant; ETR 0.78 (95% CI, 0.10 to 1.47) (table 1) [7]. On the contrary, in type 1 diabetes, total satisfaction score was significantly lower with insulin icodec compared with insulin degludec; ETD at 52 weeks -1.59 (95% CI, -2.5 to -0.67) (table 1) [8]. Compliance with insulin administration, evaluated by the Treatment Related Impact Measure for Diabetes [TRIMP-D] compliance domain score, was conducted in only 1 of the 6 studies, the ONWARDS 5 trial. The latter trial showed that compliance score was significantly higher with insulin icodec vs once-daily insulin analogues, ETD 3.04 (95% CI, 1.28 to 4.81) [7].
Safety of insulin icodec
The main concern related to safety of insulin icodec is hypoglycemia. This concern is justified given the prolonged duration of action of insulin icodec that could potentially lead to intractable hypoglycemia and recurrence of hypoglycemic episodes. Results of one short-term (7 weeks) study including 43 patients with type 2 diabetes did not show significant differences between insulin icodec and insulin glargine in terms of symptoms and hormonal response to induced hypoglycemia [9]. Despite these preliminary reassuring findings, results derived from the ONWARDS Program clearly showed increased risk of hypoglycemia with insulin icodec versus either insulin glargine or degludec. Thus, in ONWARDS 1 trial, at week 83, the rates of combined clinically significant (level 2) or severe hypoglycemia (level 3) were significantly greater with insulin icodec compared with glargine, 0.30 and 0.15 hypoglycemic events per person-year of exposure (PYE), respectively, ERR 1.71 (95% CI, 1.06 to 2.76) [3]. Moreover, the gap of hypoglycemia between insulin icodec and glargine widened with the duration of insulin use [3]. In ONWARDS 3 trial, combined level 2 and 3 hypoglycemia from baseline to week 26 was approximately 3-fold higher with insulin icodec compared with insulin degludec; ERR 3.12 (95% 1.30 to 7.51, P=0.01) [5]. In addition, in ONWARDS 2, 3 and 5 trials, there was increased risk of hypoglycemia (level 1, and combined level 2 and 3) with insulin icodec compared with insulin degludec or glargine (table 1) [4,5,7]. However, frequency of level 3 hypoglycemia and nocturnal hypoglycemia, when reported separately, was not increased with insulin icodec in the ONWARDS 1,3-5 trials [3-5,7].
In type 1 diabetes, results of ONWARDS 6 trials showed that rates of level 2 and 3 hypoglycemia with insulin icodec were approximately double the rates with degludec at 57 weeks, 17.0 versus 9.2 events per PYE [8]. Furthermore, percentage of time below 54 mg/dl measured by CGM was significantly higher with icodec than degludec, 1.0% and 0.7%, respectively; ETR 1.46 (95% CI, 1.16 to 1.85, P=0.0014) [8]. It should be emphasized that, irrespective of insulin regimen, frequency of hypoglycemia in general is much higher in patients with type 1 diabetes compared with those with type 2 diabetes. Therefore, when expressed in absolute values, the increase in number of hypoglycemic episodes related to insulin icodec was substantially greater in patients with type 1 diabetes compared with those with type 2 diabetes (table 1) [4-8].
Overall, no significant differences in weight gain were observed between patients treated with insulin icodec versus degludec or glargine except in ONWARDS 2 trials where patients randomized to insulin icodec had a mean weight gain of 1.4 kg compared to 0.3 kg weight loss in subjects receiving insulin degludec, ETD 1.7 kg (95% CI, 0.76 to 2.63, P=0.0004) (table 1) [4].
Frequency of allergic events and injection site skin reactions were not increased with the use of insulin icodec compared with insulin degludec or glargine [3-8].
Medication errors were defined as misuse or abuse of insulin that had the potential to harm the participant (e.g., overdosing insulin to maximize its effects or with the intention to cause harm) [7]. In general, no increase in medication errors was recorded with insulin icodec in patients with type 2 diabetes. Meanwhile, in patients with type 1 diabetes, 18 events of medication errors were reported in 6% of patients randomized to icodec compared with 7 such events in 2% of patients randomized to insulin degludec [8]. The causes of the latter finding were unclear but could have contributed to the increase rates of hypoglycemia in patients with type 1 diabetes who received insulin icodec in the ONWARDS 6 trial [8].
Advantages of insulin icodec
The main advantage of insulin icodec resides in its once-weekly administration. Moreover, there is some flexibility in timing of injection such that the day of administration may be changed by up to 3 days ensuring a minimum of 4 days between injections [6,7]. Additionally, a single dose-study showed that pharmacokinetics and pharmacodynamics of insulin icodec did not change significantly whether injected in the thigh, abdomen or upper arm [10]. It was not surprising therefore that in patients with type 2 diabetes satisfaction was higher with insulin icodec compared to one-daily insulin analogues. However, in type 1 diabetes, for unclear reasons, satisfaction with insulin icodec was lower than other basal insulin analogues [8]. As far as efficacy is concerned, data suggest that insulin icodec is at least as effective as once-daily insulin glargine and degludec. It is reassuring that current information suggests that insulin icodec is no more immunogenic than other basal insulins. This was reflected by the low number of allergic and injection site reactions that were generally similar to insulin glargine and degludec [3-7].
Limitations of insulin icodec
Despite the above advantages, insulin icodec suffers from the following limitations. First, the increased risk of hypoglycemia. Indeed, in patients with type 1 diabetes, the absolute difference in hypoglycemic events between insulin icodec and degludec was unacceptably high (table 1) [8]. Hence, it is unsafe at present to recommend insulin icodec for patients with type 1 diabetes. Second, insulin icodec was not studied in patients with end-stage kidney disease and those with baseline HbA1c levels > 11.0% in type 2 diabetes and HbA1c ≥ 10% in type 1 diabetes because these patients were excluded from the ONWARDS program [3-8]. Third, insulin icodec may not be convenient for use in the hospital setting where rapid variations in BG levels are expected. For instance, patients already on insulin icodec before hospital admission should be monitored closely for hypoglycemia for 7 days from the day of last icodec injection. Fourth, all available trials of insulin icodec are sponsored by the manufacturer and all ONWARDS trials, except ONWARDS 3, are open label (table 1) [3-8]. Therefore, these investigations might be virtually prone for several bias in favor of insulin icodec. Panel 1 depicts advantages and limitations of insulin icodec.
Insulin icodec is a new basal insulin formulation that can be given once-weekly. Whereas data derived from the ONWARDS Program suggests that insulin icodec may have similar or slightly superior efficacy than once-daily insulin glargine or degludec, its use may be associated with increased risk of hypoglycemia, particularly in patients with type 1 diabetes. The increased propensity for hypoglycemia with the use of insulin icodec may be attributed to its long duration and possibly inappropriate dose titration. Indeed, the up-titration schedule of icodec doses by 20 units per week, as suggested by the investigation conducted by Lingvay et al [11] and adopted in the ONWARDS Program, may be too aggressive [3-8]. Thus, less aggressive titration of insulin icodec, e.g., an increase of its dose by 10 units per week instead of 20 units, might result in less frequency of hypoglycemia. Several clinical trials are underway to assess the combination of once-weekly icodec with the once weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide in one single formulation [12-14]. The latter combination may be an attractive therapeutic strategy that potentially lowers icodec doses and therefore incidence of hypoglycemia. Moreover, the weight reduction effect of the GLP-1 RA may help lessening or even reversing the weight gain induced by insulin icodec. Importantly, large randomized trials with adequate power are required to examine the long-term effects of insulin icodec on cardiovascular events and mortality.
| ONWARDS 1 [3] | ONWARDS 2 [4] | ONWARDS 3 [5] | ONWARDS 4 [6] | ONWARDS 5 [7] | ONWARDS 6 [8] | |
| Main purpose | Compare insulin icodec (n=492) with once-daily glargine (n=492) in insulin-naïve patients with type 2 diabetes | Compare icodec (n=262) vs once-daily degludec (n=294) in basal-insulin treated patients with type 2 diabetes | Compare icodec (n=293) vs once-daily degludec (n=294) in insulin naïve-patients with type 2 diabetes | Compare icodec (n=291) vs once-daily glargine (n=291) in patients with type 2 diabetes treated with basal-bolus regimen | Compare icodec (n=542) titrated with app vs once daily OD glargine or degludec (n=538) titrated per standard practice in insulin-naïve patients | Compare icodec (n=290) vs once-daily degludec (n=292) both in combination of with insulin aspart (≥2 injections/day) in patients with type 1 diabetes |
| Design | Randomized, open-label, treat-to-target multi-national | Randomized, open-label, treat-to-target, multi-national | Randomized, double-masked, treat-to-target, multinational | Randomized, open-label, treat-to-target, multi-national | Randomized, open-label, parallel-group, multinational | Randomized, open-label, treat-to-target, multi-national |
| Duration | Main phase: 52 weeks. Extension phase 26 week. Safety monitoring until 83 weeks | 26 weeks. | 26 weeks. Safety monitoring up to 31 weeks. | 26 weeks | 52 weeks | Main phase: 26 weeks. Safety extension phase 26 weeks |
| Patients | N=984, 60% men in icodec group higher than 53% in the glargine group, 59-year-old, type 2 diabetes of 11 year-duration | N=526, 57% men, 62-year-old, type 2 diabetes of 16 year-duration | N=598, 63% men, 58-year-old, type 2 diabetes of 10 year-duration | N= 582, 52% men, 60-year-old, type 2 diabetes of 17 year-duration | N= 1,085, 57% men, 59-year-old, type 2 diabetes of 12 year-duration | N=582, 58% men, 44-year-old, type 1 diabetes of 19.5 year-duration |
| Baseline HbA1c | 8.5% | 8.1% | 8.5% | 8.3% | 8.9% | 7.6% |
| Total insulin doses per week | 214 units (30.5 units/d) with icodec vs 222 units (31.7 units/d) with glargine (no significant difference) | 268 units (38.2 units/d) with icodec vs 244 units (34.8 units/d) with degludec, ETR 1.10 (95% CI, 1.01 to 1.20) P=0.03 | 204 units (29.1 units/d) with icodec vs 187 units (26.7 units/d) with degludec (no significant difference) | 514 units (73 units/d) with icodec vs 559 units (80 units/d) with glargine. ETR 0.92 (95% CI, 0.85 to 0.99, P=0.034). | 227 units (32 units/d) with icodec vs 185 units (26.5 units/d) with OD insulin analogues. ETD 1.22 (95% CI, 1.12 to 1.33) | 311 units (44 units/d) with icodec vs 323 units (46 units/d) with degludec. ETD 0.94 (95% CI, 0.88 to 1.01) |
| Effects on HbA1c | Superior HbA1c reduction with icodec vs glargine at week 52, ETD -0.19%, 95% CI, -0.36 to -0.03, P=0.02 | Superior HbA1c reduction with icodec vs degludec, ETD -0.22% (95% CI, -0.37 to -0.08), P=0.003 | Superior HbA1c reduction with icodec vs degludec, ETD -0.2% (95% CI, -0.1 to -0.3), P=0.002 | Icodec was non-inferior to glargine. ETD 0.02% (95% CI, -0.11 to +0.15), P<0> | Superior HbA1c reduction with icodec vs OD insulins, ETD -0.38% (95% CI, -0.66 to -0.09), P=0.009 | Icodec was non-inferior to degludec. ETD 0.05% (95% CI, -0.13 to 0.23), P=0.0065. |
| Percentage of time of glucose in range (70-180 mg/dl) in CGM | 71.9% with icodec vs 66.9% with glargine, ETD 4.27% (95% CI, 1.92 to 6.62), p<0> | 63.1% with icodec vs 59.5% with degludec, ETR 1.10 (95% CI, -0.84 to +5.65) p=0.15 | Not evaluated | 66.9% with icodec vs 66.4% with glargine | Not evaluated | 59.1% with icodec vs 60.8% with degludec. ETD -2% (95% CI, -4.38 to 0.38), P=0.099. |
| Hypoglycemia level 1 (BG 54-69 mg/dl) | At week 83: 2308 events with icodec (3.02/PYE) vs 1067 events with glargine (1.39/PYE), statistical significance not mentioned) | 1209 episodes with icodec vs 589 episodes with degludec. ERR 1.88 (95% CI, 1.4 to 263, p=0.0002) | 28% (359 events in 84 patients) with icodec vs 20.1% (159 events in 59 patients) with degludec. At week 31: rates are 2.3/PYE with icodec vs 1.08 with degludec | 84% with icodec vs 86% with glargine. Yet, rate of hypoglycemic episodes was higher with icodec than glargine, ERR 1.25 (95% CI, 1.03 to 1.52), P 0.025 | 37% with icodec vs 28% with OD insulin | At week 57: 20406 events with icodec vs 14819 events with degludec (statistical significance not mentioned) |
| Incidence of combined hypoglycemia level 2 (BG <54> | At week 83: 226 events in 12.4% of patients receiving icodec vs 114 events in 13.4% receiving glargine. Event rate 0.30 with icodec vs 0.15/PYE with glargine. ERR 1.71 (95% CI, | 14% with icodec vs 7% with degludec, EOR 1.89 (95% CI, 1.05 to 3.41, p=0.034). | At 26 weeks: 8.2% with icodec vs 4.4% with degludec. ERR, 3.12 (95% CI, 1.30 to 7.51, P=0.01). At 31 weeks difference was not significant. | 52% with icodec vs 56% with glargine. 7 events of level 3 hypoglycemia with icodec vs 3 events with glargine. ERR 0.99 (95% CI, 0.73 to 1.33). Difference not significant. | 12% with icodec vs 8% with OD insulins. 0.19 events/ PYE with icodec vs 0.14 events/PYE with OD insulins, ERR 1.17 (95% CI, 0.73 to 1.86). Difference not significant. | At week 57: 5103 events in 91% of patients with icodec vs 2836 events in 86% of patients with degludec. ERR 1.80 (95% CI, 1.48 to 2.18), P<0> |
| Weight changes | +2.2 kg with icodec at week 52 vs +1.83 kg with glargine (no significant difference) | +1.4 kg with icodec vs -0.30 kg with degludec, ETD, 1.7 kg (95% CI, 0.76 to 2.63, P=0.0004) | +2.8 kg with icodec vs +2.3 kg with degludec, ETD 0.46 kg (no significant difference) | + 2.7 kg with icodec vs +2.2 kg with glargine (no significant difference) | +2.3 kg with icodec vs +1.4 with OD insulin, ETD 0.83 kg (no significant difference) | At week 52: + 1.25 kg vs +1.67 with degludec, ETD -0.42 (95% CI, -1.20 to 0.37), P=0.30 |
| Patient satisfaction score | Not evaluated | DTSQ score increased +4.22 with icodec vs +2.96 with degludec, ETD 1.25 (95% CI, 0.41 to 2.100, P=0.0035) | Not evaluated | Not evaluated | DTSQ score increased +4.68 with insulin icodec vs +3.90 with OD insulins, ETD 0.78 (95% CI, 0.10 to 1.47) | DTSQ score increased 1.41 with icodec vs 3.00 with degludec, ETD -1.59 (95% CI -2.51 to -0.67), P=0.0007 |
| Compliance with insulin administration | Not evaluated | Not evaluated | Not evaluated | Not evaluated | TRIM-D score was 90.4 with icodec vs 87.4 for OD insulins, ETD 3.0 (95% CI, 1.28 to 4.81) | Not evaluated |
Table 1: *Summary of phase 3a trials of once-weekly insulin icodec
*The primary outcome in all trials was reduction of HbA1c with insulin icodec versus comparator. Values are means.
Abbreviations in the table: OD: once daily, ETD: estimated treatment difference, ERR: estimated rate ratio, HbA1c: glycated hemoglobin, CGM: continuous glucose monitoring, PYE: hypoglycemic event per person-year of exposure. DTSQ: Diabetes Treatment Satisfaction Questionnaire. TRIM-D: Treatment Related Impact Measure for Diabetes compliance domain score.
Panel 1. Advantages and limitations of insulin icodec
1. Once-weekly dosing.
2. Higher patient satisfaction when compared with insulin degludec in patients with type 2 diabetes.
3. Increased compliance when compared with once-daily insulin analogues (degludec, glargine U100 and glargine U300) in patients with type 2 diabetes.
4. May be injected in abdomen, thigh or upper arm.
5. No increase in allergic reactions compared with insulin glargine or degludec.
6. Administration with once-weekly glucagon-like 1 receptor agonists in one formulation may be potentially effective and convenient.
1. Increased risk of hypoglycemia compared with insulin glargine and degludec, particularly in patients with type 1 diabetes.
2. Lower patient satisfaction when compared with insulin degludec in patients with type 1 diabetes.
3. Unknown long-term effects (safety was studied up to 83 weeks).
4. Propensity for hypoglycemia in cases of hospital admissions and intermittent sickness
5. Limited flexibility in dose-adjustment during days with of exercise or variable lifestyle.
6. Not studied in patients with glycated hemoglobin levels > 11.0% in type 2 diabetes and ≥10.0% in type 1 diabetes.
7. Not studied in patients with end-stage kidney disease.
8. Most clinical trials were open-label prone for bias.
The author does not have a conflict of interest to declare.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
